Mad Money 03/25/26 | Audio Only
Speakers
Summary
- Jim Cramer identifies widespread market denial, exemplified by commentators ignoring oil price drops despite Trump's diplomatic overtures to Iran, which he believes is cutting into investor performance.
- He emphasizes the "Trump put" as a real market support mechanism, where presidential rhetoric boosts stocks during downturns, citing instances where Trump talks up the market.
- Private equity firms face headwinds from overpaying for pre-AI software companies, leading to underperformance but not bankruptcy; retail investors should avoid private credit funds due to lock-ups and poor merchandise.
- Generack Holdings reports a 75% surge in data center backlog over six weeks, positioning it as a key player in AI infrastructure backup power, though the stock sold off on lack of new hyperscaler contracts.
- In a potential oil shock-induced slowdown, big pharma stocks (Pfizer, Merck, Bristol Myers) are recommended as safety plays with strong dividends (e.g., Pfizer 6.3%, Bristol Myers 4.3%) and bullish technical indicators like money flow and cup-and-handle patterns.
- Paychecks delivers a strong quarter with 20% revenue growth and a near 5% dividend yield, yet the stock is undervalued due to overblown AI disruption fears; Cramer highlights its role as an HR department for small businesses.
- Cramer is bullish on Q Electronics as part of the Dupont spin-off, citing its role in semiconductor materials and inexpensive valuation at 30-31 times earnings.
- He advises avoiding RBLX, Pen Entertainment, and Boston Properties due to sector weaknesses (gambling, office real estate structural issues) or excessive risk, labeling them "too hard."
- Early investing initiatives like Trump accounts, supported by philanthropists like Michael Dell, are championed for wealth compounding, addressing retirement savings gaps.
Trade Ideas
Cramer explicitly advised a caller not to own RBLX, stating "Don't own it. Okay? It's just not. It's too hard." The stock has consistently disappointed investors despite having great entertainment products, making it unreliable and difficult to profit from. AVOID because the investment is too challenging with poor historical performance, indicating high risk and low reward. If the company achieves a turnaround or captures more market share with the younger generation, the stock could rally, but Cramer sees it as unattractive.
Cramer agreed with Bob Lang's analysis that it's time to buy big pharma names like Pfizer, Merck, and Bristol Myers for their dividends and safety in a potential slowdown. These companies have strong dividend yields (e.g., Pfizer 6.3%, Merck nearly 3%, Bristol Myers 4.3%), bullish technical indicators (money flow, cup-and-handle patterns), and are recession-resistant as medication demand is inelastic. LONG because they offer yield protection and potential capital appreciation in a potential economic slowdown, making them defensive plays. If the economy avoids a slowdown, these stocks might underperform growth sectors; drug pipeline setbacks could impact earnings.
